ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/11/2026
Back to search
Official data from USPTO
LEAP THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LEAP THERAPEUTICS
ST13
US500000086790294Class
5
Filing
86790294
Registration
5633221
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
02/12/2026
Trademark type
Word
Nice classes
5
Filing date
10/16/2015
Registration date
12/18/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/13/2025
Last transaction
02/12/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/10/2018
First use in commerce
10/10/2018
Drawing code
4
Owner type
03
Owner location
CAMBRIDGE, MA
Examiner
KEAM, ALEX S
Current location
Historical data usage
Holders and representatives
Holders
LEAP THERAPEUTICS, INC.
CYPHERPUNK TECHNOLOGIES INC.
HealthCare Pharmaceuticals, Inc.
Representatives
John L. DuPre' Hamilton, Brook, Smith & Reynolds, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cancer and cancer-related comorbidities in humans
Publications
History of USPTO decisions and trademark events.
41 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/13/2025
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/13/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/12/2025
E815
TEAS SECTION 8 & 15 RECEIVED
10/03/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/18/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/18/2018
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/14/2018
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/13/2018
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/10/2018
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/10/2018
IUAF
USE AMENDMENT FILED
10/15/2018
EISU
TEAS STATEMENT OF USE RECEIVED
10/15/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2018
EX2G
SOU EXTENSION 2 GRANTED
05/02/2018
EXT2
SOU EXTENSION 2 FILED
05/02/2018
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/16/2017
EX1G
SOU EXTENSION 1 GRANTED
11/14/2017
EXT1
SOU EXTENSION 1 FILED
11/14/2017
EEXT
SOU TEAS EXTENSION RECEIVED
11/14/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/06/2017
TMBN
TTAB RELEASE CASE TO TRADEMARKS
04/27/2017
OP.T
OPPOSITION TERMINATED NO. 999999
04/27/2017
OP.D
OPPOSITION DISMISSED NO. 999999
04/27/2017
OP.I
OPPOSITION INSTITUTED NO. 999999
09/19/2016
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
03/22/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/22/2016
PUBO
PUBLISHED FOR OPPOSITION
03/22/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/02/2016
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/17/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/17/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
02/11/2016
ALIE
ASSIGNED TO LIE
02/10/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/10/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
02/10/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/10/2016
DOCK
ASSIGNED TO EXAMINER
02/08/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/21/2015
NWAP
NEW APPLICATION ENTERED
10/20/2015
Continuous trademark protection
Get notified about every new filing that threatens LEAP THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.